HPC Biosciences Ltd Stock Price Today (NSE: HPBL)
Fundamental Score
HPC Biosciences Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
HPC Biosciences Ltd share price today is ₹179.00, up +0.00% on NSE/BSE as of 19 February 2026. HPC Biosciences Ltd (HPBL) is a Small-cap company in the Packaging sector with a market capitalisation of ₹204.16 (Cr). The 52-week high for HPBL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 14.07x, HPBL is currently trading below its industry average P/E of 21.55x. The company has a Return on Equity (ROE) of 17.66% and a debt-to-equity ratio of 2.96.
HPC Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
HPC Biosciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
HPC Biosciences Share Price: A Financial Snapshot and Industry Context
The packaging industry is currently experiencing a shift towards sustainable and biodegradable solutions, driven by both consumer demand and regulatory pressures. This trend highlights a critical area for growth and adaptation. The current HPC Biosciences share price stands at ₹167.0, reflecting a Price-to-Earnings (PE) ratio of 14.07. This initial observation necessitates a deeper dive to assess the company's financial health and potential for sustainable value creation. This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra.
Comparing HPC Biosciences with its sector peers offers valuable context. While
Subam Papers Ltd operates in a related space, differences in management quality, as evidenced by their strategic decisions and capital allocation, are crucial. It would be prudent to compare the consistency of HPC Biosciences' earnings against the more volatile earnings of its peer.A key strength of HPC Biosciences appears to be its Return on Capital Employed (ROCE) of 13.23%. This indicates the company's efficiency in generating profits from its invested capital. A consistently high ROCE contributes to building a strong economic moat, enabling the company to withstand competitive pressures and maintain profitability. This ability to reinvest profits at a rate exceeding its cost of capital will drive long-term growth.
However, the PE ratio of 14.07 must be considered relative to the industry average and growth prospects. A closer examination of HPC Biosciences' debt levels, cash flow generation, and future expansion plans is essential to determine whether the current valuation is justified. Further investigation into the competitive landscape and the company's market share will also provide a more complete picture of its potential for continued success within the evolving packaging sector. Careful observation of these factors will be essential to assessing future potential.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
HPC Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HPBL across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Return on Equity (17.66%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Attractive Valuation (P/E: 14.07 vs Industry: 21.55)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (164.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (68.86%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Elevated Debt Levels (D/E: 2.96)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Negative Free Cash Flow (₹-171.58 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 9.30%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
HPC Biosciences Ltd Financial Statements
Comprehensive financial data for HPC Biosciences Ltd including income statement, balance sheet and cash flow
About HPBL (HPC Biosciences Ltd)
HPC Biosciences Ltd (HPBL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Packaging sector with a current market capitalisation of ₹204.16 (Cr). HPC Biosciences Ltd has delivered a Return on Equity (ROE) of 17.66% and a ROCE of 13.23%. The debt-to-equity ratio stands at 2.96, reflecting the company's capital structure. Investors tracking HPBL share price can monitor key metrics including P/E ratio, promoter holding of 75.00%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
HPBL Share Price: Frequently Asked Questions
What is the current share price of HPC Biosciences Ltd (HPBL)?
As of 19 Feb 2026, 10:09 am IST, HPC Biosciences Ltd share price is ₹179.00. The HPBL stock has a market capitalisation of ₹204.16 (Cr) on NSE/BSE.
Is HPBL share price Overvalued or Undervalued?
HPBL share price is currently trading at a P/E ratio of 14.07x, compared to the industry average of 21.55x. Based on this relative valuation, the HPC Biosciences Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of HPBL share price?
The 52-week high of HPBL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the HPC Biosciences Ltd share price?
Key factors influencing HPBL share price include quarterly earnings growth (Sales Growth: 68.86%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is HPC Biosciences Ltd a good stock for long-term investment?
HPC Biosciences Ltd shows a 5-year Profit Growth of N/A% and an ROE of 17.66%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 2.96 before investing in HPBL shares.
How does HPC Biosciences Ltd compare with its industry peers?
HPC Biosciences Ltd competes with major peers in the Packaging. Investors should compare HPBL share price P/E of 14.07x and ROE of 17.66% against the industry averages to determine competitive standing.
What is the P/E ratio of HPBL and what does it mean?
HPBL share price has a P/E ratio of 14.07x compared to the industry average of 21.55x. Investors pay ₹14 for every ₹1 of annual earnings.
How is HPBL performing according to Bull Run's analysis?
HPBL has a Bull Run fundamental score of 39.9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does HPBL belong to?
HPBL operates in the Packaging industry. This classification helps understand the competitive landscape and sector-specific trends affecting HPC Biosciences Ltd share price.
What is Return on Equity (ROE) and why is it important for HPBL?
HPBL has an ROE of 17.66%, which indicates excellent management efficiency. ROE measures how efficiently HPC Biosciences Ltd generates profits from shareholders capital.
How is HPBL debt-to-equity ratio and what does it indicate?
HPBL has a debt-to-equity ratio of 2.96, which indicates high leverage that increases financial risk.
What is HPBL dividend yield and is it a good dividend stock?
HPBL offers a dividend yield of 0.52%, meaning you receive ₹0.52 annual dividend for every ₹100 invested in HPC Biosciences Ltd shares.
How has HPBL share price grown over the past 5 years?
HPBL has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in HPBL and why does it matter?
Promoters hold 75.00% of HPBL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in HPC Biosciences Ltd.
What is HPBL market capitalisation category?
HPBL has a market capitalisation of ₹204 crores, placing it in the Small-cap category.
How volatile is HPBL stock?
HPBL has a beta of N/A. A beta > 1 suggests the HPC Biosciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is HPBL operating profit margin trend?
HPBL has a 5-year average Operating Profit Margin (OPM) of 5.83%, indicating the company's operational efficiency.
How is HPBL quarterly performance?
Recent quarterly performance shows HPC Biosciences Ltd YoY Sales Growth of 68.86% and YoY Profit Growth of 164.00%.
What is the institutional holding pattern in HPBL?
HPBL has FII holding of 4.50% and DII holding of 4.80%. Significant institutional holding often suggests professional confidence in the HPC Biosciences Ltd stock.